EBOS Group Limited (ASX:EBO)
Australia · Delayed Price · Currency is AUD | Market Cap | 3.38B -35.5% |
| Revenue (ttm) | 13.49B +9.9% |
| Net Income | 225.19M +4.7% |
| EPS | 1.09 +0.1% |
| Shares Out | n/a |
| PE Ratio | 15.03 |
| Forward PE | 13.59 |
| Dividend | 1.03 (6.31%) |
| Ex-Dividend Date | Aug 27, 2026 |
| Volume | 89,111 |
| Open | 16.69 |
| Previous Close | 16.29 |
| Day's Range | 16.17 - 16.69 |
| 52-Week Range | 15.68 - 26.75 |
| Beta | 0.15 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2026 |
About EBOS Group
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through the Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; pharmacy data, consumer loyalty, and analytics services; and health communications, programs, and consultancy services. It also offers community-based health care services and programs; vitamins, mi... [Read more]
Financial Performance
In fiscal year 2026, EBOS Group's revenue was 13.49 billion, an increase of 9.94% compared to the previous year's 12.27 billion. Earnings were 225.19 million, an increase of 4.67%.
Financial StatementsNews
EBOS Group FY26 Results Rise, Sees Higher FY27 Underlying EBITDA; Stock Up - Update
(RTTNews) - EBOS Group Ltd. (EBOSF, EBO.AX), an Australian provider of healthcare and animal care products, reported Wednesday higher results for fiscal 2026. Further, the firm maintained fividend, an...
EBOS Group Earnings Call Transcript: H2 2026
Revenue grew 9.9% to AUD 13.5 billion and underlying EBITDA rose 5% to AUD 614 million, with strong performance across all divisions and completion of a major distribution center renewal program. FY 2027 guidance targets mid-single-digit EBITDA growth, supported by lower CapEx and ongoing productivity initiatives.
EBOS Group Slides: H2 2026
EBOS Group has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 18, 2026.
EBOS Group Earnings release: H2 2026
EBOS Group released its H2 2026 earnings on August 18, 2026, summarizing the period's financial results.
EBOS Group Annual report: H2 2026
EBOS Group has published its H2 2026 annual report on August 18, 2026.
EBOS Group Transcript: Investor Day 2026
EBITDA is set to triple over a decade as the portfolio shifts toward higher-growth, higher-return sectors, with 85% of earnings now from market-leading businesses. Major capital investments are concluding, enabling a focus on productivity, recurring earnings, and disciplined bolt-on M&A for future growth.
EBOS Group Slides: FY 2026
EBOS Group has posted slides in relation to its FY 2026 quarterly earnings report, which was published on April 29, 2026.
EBOS Group Earnings Call Transcript: H1 2026
Revenue grew 13% to AUD 6.8 billion, with underlying EBITDA up 3.2% to AUD 300 million and strong performances across Healthcare and Animal Care. FY 2026 EBITDA guidance is reaffirmed, with margin and cash flow improvements expected as the DC Renewal Program concludes and CapEx steps down.
EBOS Group Quarterly report: H1 2026
EBOS Group has published its H1 2026 quarterly earnings report on February 24, 2026.
EBOS Group Slides: H1 2026
EBOS Group has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 24, 2026.
EBOS Group Earnings release: H1 2026
EBOS Group released its H1 2026 earnings on February 24, 2026, summarizing the period's financial results.
EBOS Group Transcript: AGM 2025
The meeting reviewed strong revenue growth and strategic investments, but addressed challenges from the loss of a major contract, margin pressures, and a significant share price decline. Executive incentives were updated to better align with shareholder interests, and all board resolutions proceeded to vote.
EBOS Group Slides: FY 2025
EBOS Group has posted slides in relation to its FY 2025 quarterly earnings report, which was published on October 28, 2025.